Rising Prevalence Of Pneumococcal Contamination Drives Growth In Pneumococcal Vaccine Market Is Supporting Development Across The Pneumococcal Vaccine Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Pneumococcal Vaccine Market Progress Through 2030?

The pneumococcal vaccine market has experienced significant expansion over recent years. This market is projected to expand from $9.4 billion in 2025 to $9.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. Historically, this growth was driven by factors such as the substantial burden of childhood pneumonia, the integration into national immunization programs, robust backing from global health organizations, increasing public awareness of invasive pneumococcal disease, and the demonstrated effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience substantial expansion in the coming years, anticipated to reach $12.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the forecast period include the introduction of next-generation PCV vaccines, wider adult vaccination recommendations, improved healthcare accessibility in developing nations, escalating worries about antimicrobial resistance, and government investment in preventive immunization programs. Key trends emerging in the forecast period encompass the broadening of conjugate vaccines to cover more serotypes, an intensified emphasis on immunization programs for children and the elderly, the increasing implementation of combination and booster vaccination approaches, enhanced public-private collaborations to boost immunization coverage, and the expansion of preventive healthcare alongside national immunization schedules.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Primary Factors Are Fueling The Expansion Of The Pneumococcal Vaccine Market?

The rising incidence of pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market in the coming years. This type of contamination signifies infections stemming from the bacterium Streptococcus pneumoniae, also known as pneumococcus, manifesting as conditions like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine functions by prompting the body to generate antibodies against pneumococcal bacteria, effectively reducing or eliminating disease-causing bacteria and their toxins, thereby safeguarding children, the elderly, and individuals with compromised immune systems against various forms of pneumococcal infections. As an illustration, data from July 2025, provided by the Immunisation Coalition, an Australia-based, independent not-for-profit charity, indicates a consistent annual rise in invasive pneumococcal disease (IPD) cases, escalating from 1,869 in 2022 to 2,265 in 2023, and subsequently to 2,379 in 2024. Consequently, the escalating occurrence of pneumococcal contamination is serving as a primary impetus for the growth of the pneumococcal vaccine market.

What Key Segment Areas Are Included In The Pneumococcal Vaccine Market Assessment?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Which Trends Are Guiding The Development Of The Pneumococcal Vaccine Market?

Leading companies within the pneumococcal vaccine market are introducing innovative products to boost their market profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, launched its V116 vaccine. This V116 vaccine is engineered to address the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Relative to other pneumococcal vaccines, V116 has exhibited enhanced immunogenicity across various serotypes in adult populations, and it has also generated positive immune responses in individuals who have not received prior vaccination as well as those previously vaccinated. The U.S. Food and Drug Administration (FDA) has categorized V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Who Are The Leading Firms Participating In The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Access The Complete Pneumococcal Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Region Stands As The Largest Contributor To The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pneumococcal Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795